Novel protein kinase inhibitor TT-00420 inhibits gallbladder cancer by inhibiting JNK/JUN-mediated signaling pathway
Huijie Miao,Yajun Geng,Yang Li,Shijie Tang,Feiling Feng,Weijian Li,Yongsheng Li,Liguo Liu,Rui Zhang,Shimei Qiu,Ying Wu,Zeyu Wang,Ziyi Wang,Ziyu Shao,Ke Liu,Lu Zou,Mao Yang,Yuhao Zhao,Chen Chen,Zhizhen Li,Dadong Zhang,Peng Peng,Xiaoyan Qiang,Frank Wu,Yongning He,Luonan Chen,Dongxi Xiang,Xiaoqing Jiang,Maolan Li,Yun Liu,Yingbin Liu
DOI: https://doi.org/10.1007/s13402-022-00692-7
IF: 7.051
2022-01-01
Cellular Oncology
Abstract:Purpose This study aimed to investigate the efficiency of our chemically synthesized TT-00420, a novel spectrum-selective multiple protein kinase inhibitor, in cultured cells and animal models of gallbladder cancer (GBC) and explore its potential mechanism. Methods Multiple GBC models were established to assess the anti-tumor efficiency, toxicity, and pharmacokinetics of TT-00420. Integrated transcriptomic, proteomic and phosphoproteomic analysis was conducted to identify potential downstream effectors of TT-00420. Western blotting, qRT-PCR, nuclear-cytoplasm separation, and immunofluorescence were performed to confirm the multi-omic results and explore the molecular mechanism of TT-00420. Immunohistochemistry was used to detect FGFR1 and p-FGFR1 expression levels in GBC samples. Autodock software was utilized to investigate the potential binding mode between the TT-00420 and the human FGFR1. Results We found that TT-00420 exerted potent growth inhibition of GBC cell lines and multiple xenograft models. Treatment of mice with 15 mg/kg TT-00420 via gavage displayed a half-life of 1.8 h in the blood and rapid distribution to the liver, kidneys, lungs, spleen, and tumors at 0.25 h, but no toxicity to these organs over 2 weeks. Multi-omic analysis revealed c-Jun as a potential downstream effector after TT-00420 treatment. Mechanistically, TT-00420 showed rigorous ability to block FGFR1 and its downstream JNK-JUN (S63/S73) signaling pathway, and induce c-Jun S243-dependent MEK/ERK reactivation, leading to FASLG-dependent tumor cell death. Finally, we found that FGFR1 and p-FGFR1 expression was elevated in GBC patients and these levels correlated with decreased patient survival. Conclusions TT-00420 shows potent antitumor efficacy and may serve as a novel agent to improve GBC prognosis.